Bladder Cancer VL

Surveillance Guidelines for Low-Grade Ta NMIBC Often Not Followed - Stephen Williams

Details
Low-risk non-muscle-invasive bladder cancer (NMIBC) is associated with extremely low rates of progression and cancer-specific mortality; however, patients with low-risk NMIBC may often receive non-guideline-recommended and potentially costly surveillance testing and treatment. The objective of this study was to describe current surveillance and treatment practices, cancer outcomes, and costs of ca...

Microbiome Research in Bladder Cancer - Laura Bukavina

Details
Ashish Kamat is joined by Laura Bukavina to discuss her work on the Microbiome of Bladder Cancer. Currently, we have little knowledge about the microbiome and bladder cancer. The research being done at Fox Chase and Case Western is comparing the beta diversity of bladder cancer patients compared to healthy controls to help think of ways to modulate the microbiome to improve the treatment of patien...

Realities of Bladder Cancer In Women - Sima Porten, Kristen Scarpato, Svetlana Avulova & Anne Schuckman

Details
Kristen Scarpato, Svetlana Avulova, and Anne Schuckman join Sima Porten in this conversation on the realities of diagnosis and treatment of bladder cancer in women. They start by evaluating a patient case to highlight some women who present with bladder cancer and discuss what's most important when we talk about caring for these patients and how to improve care. Biographies: Sima P. Porten, MD, MP...

Busting Common Myths Regarding Bladder Preservation for Muscle Invasive Bladder Cancer - Nick James & Ananya Choudhury

Details
Ashish Kamat, Ananya Choudhury, and Nick James discuss trimodal therapy, or radiotherapy, for bladder preservation in patients with bladder cancer. Dr. Choudhury touches on how to differentiate treatment between moving towards cystectomy and deciding on radiotherapy. They also discuss differing radiotherapy schedules and how those differences can affect patients. Biographies: Ananya Choudhury, MA,...

Urethral Recurrence after Radical Cystectomy for Bladder Cancer - Ekaterina Laukhtina

Details
Ekaterina Laukhtina and Ashish Kamat discuss urethral recurrence after radical cystectomy. Dr. Laukhtina goes into depth on using urethroscopy to diagnose urethral recurrence as well as when urethrectomy may be useful highlighting a systematic review and meta-analysis assessing the incidence and risk factors of urethral recurrence as well as summarizing data on survival outcomes in patients with u...

The Role of Bladder-Sparing Trimodality Therapy - Sophia Kamran

Details
Sophia Kamran joins Sam Chang to discuss her presentation from the GU ASCO 2022 Annual Meeting focusing on novel therapies in bladder cancer and their toxicities, discussing the role of bladder-sparing trimodality therapy with a focus on toxicity and functional outcomes. Biographies: Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology, Harvard Medical School, Massachusetts General Hosp...

Biological Pathways in Urothelial Carcinoma - Carissa Chu

Details
Carissa Chu joins Sam Chang to discuss data on genetic changes and alterations in urothelial carcinoma. The purpose of the study is to characterize human epidermal growth factor receptor 2 (HER2) (ERBB2) and fibroblast growth factor receptor 3 (FGFR3) mutations in a prospectively collected cohort of urothelial cancers. Dr. Chu highlights the key findings from this study. Biographies: Carissa Chu,...

Treating Women with Bladder Cancer and a Community Approach to Navigating a Diagnosis - Jeannie Hoffman-Censits & Elizabeth Guancial

Details
Alicia Morgans is joined by Jeannie Hoffman-Censits and Elizabeth Guancial to discuss the challenges women face navigating a bladder cancer diagnosis. In 2022, the American Cancer Society estimates more than 81,000 will be diagnosed with bladder cancer in the United States. Of those, 61,700 will be men, and 19,480 will be women. Drs. Morgans, Hoffman-Censits, and Guancial discuss the importance of...

Comparative Effectiveness of Radical Cystectomy and Trimodality Therapy for Muscle-Invasive Bladder Cancer – Boris Gershman

Details
Ashish Kamat and Boris Gershman discuss radical cystectomy versus trimodal therapy for muscle-invasive urothelial carcinoma of the bladder. Dr. Gershman gives an in-depth background on the pros and cons of radical cystectomy and trimodal therapy for muscle-invasive urothelial carcinoma, while also describing which may be better for these patients. They also discuss the hopes that, as a community,...

Research in Biomarkers for Bladder Cancer - The BCAN Young Investigator Awards - Benjamin Miron

Details
Benjamin Miron, a 2021 recent recipient of the Bladder Cancer Advocacy Network's (BCAN) Young Investigator Award joins Alicia Morgans to speak about the Young Investigator Award Program. Dr. Miron speaks on the importance of this program and the opportunity it provides young investigators to jumpstart their careers. This funding Dr. Miron received helped to investigate new biomarkers for bladder c...
email news signup